This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Alexion Pharmaceuticals, Inc.. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Scott Edward Moseley: Innovator in Hypophosphatasia Treatment
Introduction
Scott Edward Moseley is a notable inventor based in Arlington, MA (US). He has made significant contributions to the field of medicine, particularly in the treatment of hypophosphatasia (HPP). His innovative approach has the potential to improve the quality of life for patients suffering from this rare condition.
Latest Patents
Scott Edward Moseley holds a patent for "Methods for treating hypophosphatasia (HPP) in adults and adolescents." This patent outlines methods for treating HPP in patients exhibiting decreased pyrophosphate (PPi) or pyridoxal 5'-phosphate (PLP) concentrations. The treatment involves administering a soluble alkaline phosphatase (sALP) to patients, which can help alleviate physical impairments and improve walking ability.
Career Highlights
Scott is currently associated with Alexion Pharmaceuticals, Inc., where he continues to work on innovative solutions for rare diseases. His expertise and dedication to research have positioned him as a key figure in the pharmaceutical industry.
Collaborations
Throughout his career, Scott has collaborated with talented professionals, including Andrew Evan Denker and Wei-Jian Pan. These collaborations have fostered a productive environment for innovation and research.
Conclusion
Scott Edward Moseley's contributions to the treatment of hypophosphatasia highlight his commitment to advancing medical science. His work not only showcases his inventive spirit but also reflects the importance of collaboration in achieving breakthroughs in healthcare.